Mangalam Drugs explores Vapi asset sale tied to 32% revenue
Key highlights
- Mangalam Drugs approved exploration of Unit-2 strategic options on November 18, 2026.
- Unit-2 reported Rs 74.46 crore of last-year revenue or turnover, equal to 32% of the company total.
- Mangalam Drugs reported Rs 232.90 crore of revenue or total income in the last financial year.
- No buyer, valuation, consideration or completion date has been disclosed for the proposed Unit-2 disposal.
powered by IRIS

Mangalam Drugs and Organics Limited is exploring sale or disposal of Vapi Unit-2 leasehold land rights and building, an undertaking that generated Rs 74.46 crore, or 32%, of last financial year's Rs 232.90 crore revenue or total income. No buyer, valuation or definitive agreement exists as of November 18, 2026.
Know Mangalam Drugs and Organics inside out
Results, valuation, peers and who's buying, in one view.
What has Mangalam Drugs approved for Unit-2?
Mangalam Drugs approved a financial-restructuring review on November 18, 2026 that includes exploring strategic options, including a potential sale or disposal of leasehold land rights and a building at Unit-2, Plot No. 1203, Gujarat Industrial Development Corporation, or GIDC, Vapi, in Gujarat's Valsad district. The filing describes the subject as an undertaking and does not announce a completed property sale.
Mangalam Drugs also approved convening an Extra-Ordinary General Meeting, or EGM, in financial year 2026-27 to seek member approval wherever applicable and authorise the board to take necessary actions. The board meeting on November 18 began at 2:30 p.m. and concluded at 5:00 p.m., according to the Regulation 30 disclosure.
The November 18 approval authorises exploration rather than a binding transaction. Mangalam Drugs said it had not entered into a definitive agreement or arrangement for the proposed disposal, and that commercial details would be decided at an appropriate stage, subject to necessary approvals and applicable laws.
How material was Unit-2 to Mangalam Drugs revenue?
Unit-2 accounted for Rs 74.46 crore of revenue or turnover in the last financial year, equal to 32% of Mangalam Drugs' Rs 232.90 crore revenue or total income. The filing records the same Rs 74.46 crore and 32% contribution for Unit-2 total income, but does not state a net-worth contribution for the undertaking.
The disclosed comparison means the review covers an undertaking responsible for nearly one-third of reported revenue or total income in the stated period. Based on the figures in the filing, revenue or total income outside Unit-2 was Rs 158.44 crore, although Mangalam Drugs did not divide that amount by unit, product, customer or business segment.
Mangalam Drugs did not disclose Unit-2 profit, carrying value of assets, debt, cash flow, production capacity or employee data in its November 18 filing. It also provided no net-worth amount or percentage for the undertaking, limiting the numerical disclosure to revenue and total-income contribution.
Got a follow-up? Ask IRIS
What sale terms has Mangalam Drugs not decided?
No buyer, consideration, valuation, commercial terms or completion date has been decided for the potential Unit-2 disposal. Mangalam Drugs said no prospective buyer had been identified or finalised as of November 18, and it would disclose buyer details after identification and finalisation in line with applicable regulatory requirements.
The consideration receivable, if any, has not been determined because no valuation or definitive commercial terms have been finalised. The Rs 74.46 crore annual revenue contribution therefore measures the undertaking's reported scale, rather than representing an estimate of transaction value or cash proceeds.
Completion timing is not ascertainable, according to the filing. Mangalam Drugs said any timing depends on identifying a suitable buyer, finalising commercial terms and receiving statutory, regulatory and shareholder approvals wherever required; it gave neither a target signing date nor an EGM date.
Mangalam Drugs has not stated whether Unit-2 activities would continue, relocate, transfer with the property or cease after an eventual transaction. Its November 18 approval to explore various strategic options does not commit the company to a particular buyer, disposal structure or operating outcome.
Which approvals and transaction routes could apply?
A completed Unit-2 disposal could require shareholder approval and regulatory compliance, but Mangalam Drugs said the precise requirements will be assessed after the transaction structure and terms are settled. The planned EGM in financial year 2026-27 is intended to seek member approval wherever applicable and authorise the board to take required steps.
Mangalam Drugs said the proposed disposal is being explored independently and is not part of a Scheme of Arrangement. It will assess the applicability of Regulation 37A of the Securities and Exchange Board of India, or SEBI, Listing Obligations and Disclosure Requirements, or LODR, Regulations after the final structure and terms are known.
Mangalam Drugs has not decided whether a transaction would take the form of a slump sale. The company said disclosures applicable to that route are not applicable at this exploratory stage because no decision has been taken on the mode or structure of the disposal.
Related-party requirements are also unresolved at the November 18 stage. Mangalam Drugs said it will examine their applicability after identifying the buyer and finalising the transaction, and that any related-party transaction would require applicable approvals and compliance, including arm's-length requirements where relevant.
Conclusion
Mangalam Drugs has begun a review of a Vapi Unit-2 property undertaking that represented Rs 74.46 crore, or 32%, of last financial year's Rs 232.90 crore revenue or total income. The disclosed proportion makes the proposal relevant to the reported operating base, but the filing contains no sale price, buyer, valuation, completion date or decision on the transaction route.
The next disclosed step is an EGM in financial year 2026-27, for which Mangalam Drugs has not announced a date. The matters to watch are identification of a buyer, commercial terms and consideration, the intended treatment of Unit-2 operations, and the final assessment of shareholder, Regulation 37A and related-party requirements.


